Walther E U, Dang T, Hartung H P, Hohlfeld R
Neurologische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, München.
Nervenarzt. 1997 Dec;68(12):935-9. doi: 10.1007/s001150050219.
Interferon beta-1b has been shown to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). In the North American study, however, approximately 35% of patients developed neutralizing antibodies leading to a diminution of therapeutic efficacy according to current investigations. In contrast, antibody-negative patients showed a 50% reduction in the annual relapse rate compared to patients receiving placebo. Here we provide practical guidelines for neutralizing antibody testing if treatment failure is suspected.
β-1b干扰素已被证明可降低复发缓解型多发性硬化症（MS）病情加重的频率和严重程度。然而，在北美进行的研究中，根据目前的调查，约35%的患者产生了中和抗体，导致治疗效果减弱。相比之下，抗体阴性的患者与接受安慰剂治疗的患者相比，年复发率降低了50%。在此，我们提供了在怀疑治疗失败时进行中和抗体检测的实用指南。
